These findings underscore Complexes 2 and 2‘s’ promise as multifaceted anticancer agents, combining effective EGFR inhibition and mitochondrial apoptosis induction, and highlight their potential for radiopharmaceutical applications in overcoming therapeutic limitations in EGFR-overexpressing cancers. The gene discussed is EGFR; the disease is cancer.